NEW YORK (360DX) – Texas-based United Allergy Services filed suit against Quest Diagnostics late last month, accusing the lab giant of conspiring with other market players to eliminate lower-priced competition.

The allergy company alleges that Quest and co-conspirators have cost the company $200 million in lost profits. Specifically, the suit alleges that Quest and other players in the industry convinced insurers and potential UAS customers that doing business with UAS "caused medical, legal and other risks."

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Feb
22
Sponsored by
SeraCare

This webinar will walk through key considerations and helpful guidelines to accelerate next-generation sequencing (NGS)-based clinical genomics assay validation for less money and greater confidence in results.

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Mar
13

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

Apr
03

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.